Serum leptin and adiponectin levels and risk of renal cell carcinoma

Obesity

Volumn 21, Issue 7, 2013, Pages 1478-1485

  Liao, Linda M ^a   Schwartz, Kendra ^b   Pollak, Michael ^c   Graubard, Barry I ^a   Li, Zhen ^c   Ruterbusch, Julie ^b   Rothman, Nathaniel ^a   Davis, Faith ^d   Wacholder, Sholom ^a   Colt, Joanne ^a   Chow, Wong Ho ^a   Purdue, Mark P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; LEPTIN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BODY MASS; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; OBESITY; POPULATION BASED CASE CONTROL STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEX DIFFERENCE; UNITED STATES;

EID: 84881549679     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20138     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 2010; 60: 277-300.
2. Chow WH, Devesa SS, Warren JL, Fraumeni JF, Jr., Rising incidence of renal cell cancer in the United States. JAMA 1999; 281: 1628-1631.
3. Stafford HS, Saltzstein SL, Shimasaki S, Sanders C, Downs TM, Robins Sadler G,. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol 2008; 179: 1704-1708.
4. Chow WH, Dong LM, Devesa SS,. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010; 7: 245-257.
5. Vaishampayan UN, Do H, Hussain M, Schwartz K,. Racial disparity in incidence patterns and outcome of kidney cancer. Urology 2003; 62: 1012-1017.
6. Calle EE, Kaaks R,. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-591.
7. Chow WH, Gridley G, Fraumeni JF, Jr., Jarvholm B,. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000; 343: 1305-1311.
8. Luo J, Margolis KL, Adami HO, Lopez AM, Lessin L, Ye W,. Body size, weight cycling, and risk of renal cell carcinoma among postmenopausal women: the Women's Health Initiative (United States). Am J Epidemiol 2007; 166: 752-759.
9. Adams KF, Leitzmann MF, Albanes D, et al. Body size and renal cell cancer incidence in a large US Cohort Study. Am J Epidemiol 2008;168:268 - 277.
10. Renehan AG, Roberts DL, Dive C,. Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem 2008; 114: 71-83.
11. Fischer-Posovszky P, Wabitsch M, Hochberg Z,. Endocrinology of adipose tissue-an update. Horm Metab Res 2007; 39: 314-321.
12. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-295.
13. Ruhl CE, Everhart JE,. Leptin concentrations in the United States: relations with demographic and anthropometric measures. Am J Clini Nutr 2001; 74: 295-301.
14. Garofalo C, Surmacz E,. Leptin and cancer. J Cell Physiol 2006; 207: 12-22.
15. Housa D, Housova J, Vernerova Z, Haluzik M,. Adipocytokines and cancer. Physiol Res 2006; 55: 233-244.
16. Tilg H, Moschen AR,. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-783.
17. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
18. Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46: 459-469.
19. Kadowaki T, Yamauchi T,. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439-451.
20. Flegal KM, Carroll MD, Ogden CL, Curtin LR,. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-241.
21. Cohen SS, Gammon MD, Signorello LB, et al. Serum adiponectin in relation to body mass index and other correlates in black and white women. Ann Epidemiol 2011; 21: 86-94.
22. Cohen SS, Fowke JH, Cai Q, et al. Differences in the association between serum leptin levels and body mass index in Black and White Women: a report from the Southern Community Cohort Study. Ann Nutr Metab 2012; 60: 90-97.
23. Colt JS, Schwartz K, Graubard BI, et al. Hypertension and risk of renal cell carcinoma among white and black americans. Epidemiology 2011; 22: 797-804.
24. Rothman KJ, Greenland S, Walker AM,. Concepts of interaction. Am J Epidemiol 1980; 112: 467-470.
25. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M,. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578.
26. Spyridopoulos TN, Petridou ET, Dessypris N, et al. Inverse association of leptin levels with renal cell carcinoma: results from a case-control study. Hormones (Athens) 2009; 8: 39-46.
27. Li L, Gao Y, Zhang LL, He DL,. Concomitant activation of the JAK/STAT3 and ERK1/2 signaling is involved in leptin-mediated proliferation of renal cell carcinoma Caki-2 cells. Cancer Biol Ther 2008; 7: 1787-1792.
28. Drabkin HA, Gemmill RM,. Obesity, cholesterol, and clear-cell renal cell carcinoma (RCC). Adv Cancer Res 2010; 107: 39-56.
29. Horiguchi A, Sumitomo M, Asakuma J, et al. Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma. J Urol 2006; 176: 1631-1635.
30. Horiguchi A, Sumitomo M, Asakuma J, et al. Leptin promotes invasiveness of murine renal cancer cells via extracellular signal-regulated kinases and rho dependent pathway. J Urol 2006; 176: 1636-1641.
31. Miyoshi Y, Funahashi T, Kihara S, et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003; 9: 5699-5704.
32. Mantzoros C, Petridou E, Dessypris N, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004; 89: 1102-1107.
33. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS,. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005; 97: 1688-1694.
34. Cust AE, Kaaks R, Friedenreich C, et al. Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. J Clin Endocrinol Metab 2007; 92: 255-263.
35. Dal Maso L, Augustin LS, Karalis A, et al. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 2004; 89: 1160-1163.
36. Spyridopoulos TN, Petridou ET, Skalkidou A, Dessypris N, Chrousos GP, Mantzoros CS,. Low adiponectin levels are associated with renal cell carcinoma: a case-control study. Int J Cancer 2007; 120: 1573-1578.
37. Pinthus JH, Kleinmann N, Tisdale B, et al. Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear-cell carcinoma of the kidney. Eur Urol 2008;54:866 - 873.
38. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS,. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clini Nutr 2007; 86: s858-s866.
39. Smith LM, Yao-Borengasser A, Starks T, Tripputi M, Kern PA, Rasouli N,. Insulin resistance in African-American and Caucasian women: differences in lipotoxicity, adipokines, and gene expression in adipose tissue and muscle. J Clin Endocrinol Metab 2010; 95: 4441-4448.
40. Wassel CL, Pankow JS, Jacobs DR, Jr., Steffes MW, Li N, Schreiner PJ,. Variants in the adiponectin gene and serum adiponectin: the Coronary Artery Development in Young Adults (CARDIA) Study. Obesity (Silver Spring) 2010; 18: 2333-2338.